An Open-Label, Two-Part Sequential Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD0780 and the Absolute Bioavailability of AZD0780 in Healthy Male Subjects
Latest Information Update: 11 Aug 2023
At a glance
- Drugs AZD 0780 (Primary) ; AZD 0780 (Primary)
- Indications Cardiovascular disorders; Dyslipidaemias
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 08 Aug 2023 Status changed from recruiting to completed.
- 16 May 2023 Planned number of patients changed from 8 to 10.
- 16 May 2023 Planned End Date changed from 24 May 2023 to 5 Jun 2023.